This premier B2B event provides the appropriate platform to engage and discuss ideas with your peers, while facilitating a professional atmosphere and environment for good company representation and development.
The summit will shed light on the implementation of recent updates to the ICH M7 guidelines in regard to genotoxic impurities.
It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Vienna this coming June!
Key Practical Learning Points of the Summit:
Who Should Attend:
Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:
Dr. Andrew Teasdale Principle Scientist AstraZeneca, UK
Dr. Larry Wigman Principal Scientific Manager (SMACQC) Genentech, US
Dr. Laura Custer Head of Genetic Toxicology, Associate Director Bristol-Myers Squibb, US
Dr. Fenghe Qiu Senior Research Fellow Boehringer Ingelheim Pharmaceuticals Inc, US
Dr. Lutz Müller Project Leader in Pharmaceutical Sciences F. Hoffmann-La Roche Innovation Center Basel, Switzerland
Dr. Raphael Nudelman Director, Chemical & Computational Toxicology Teva Pharmaceutical Industries Ltd., Israel
Dr. Alexander Amberg Head of In Silico Toxicology R&D Preclinical Safety FF Sanofi-Aventis Deutschland GmbH, Germany
Dr. Jacques Van Gompel EU Head Genetic Toxicology Mechanistic & Investigative Toxicology Discovery Sciences Janssen Pharmaceutica NV, Belgium
Dr. Roustem Saiakhov President MultiCASE Incorporated, US
Dr. Catrin Hasselgren Senior Principal Scientist Leadscope, Inc., US
Dr. Ir. Lise Vanderkelen Dep. Head Pharma Services Toxikon Europe nv, Belgium
Dr. David Snodin Independent Consultant Xiphora Biopharma Consulting, UK
Dr. Patrick Reichl Sr. Scientific Professional Shire, Austria
Please, complete details below:
Please, complete details below and you will get Agenda via E-mail:
Please, complete details below and you will get 500 € Document Package: